#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15816	16S	1529	1529	100.0	16S.l15.c17.ctg.2	2271	837.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1448	1448	C	1036	C,G	1034,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4100	809.9	0	.	n	.	0	T695C	SNP	695	695	T	1316	1316	C	976	C,T,G,A	973,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4100	809.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1958	1958	A	1148	A,G	1147,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4100	809.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2592	2592	C	1000	C,G,T	997,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4100	809.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2666	2666	A	906	A,T	905,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26636	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4100	809.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3218	3218	C	921	C,A,G	918,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2148	folP	852	852	100.0	folP.l15.c4.ctg.1	1927	138.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1152	1154	AGC	210;208;208	A;G,T;C,G	210;207,1;207,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5190	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3955	163.7	1	SNP	p	S91F	0	.	.	271	273	TCC	880	882	TCC	169;168;168	T;C;C,T	169;168;167,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5190	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3955	163.7	1	SNP	p	D95G	0	.	.	283	285	GAC	892	894	GAC	174;176;175	G,C;A;C	173,1;176;175	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5190	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3955	163.7	1	SNP	p	D95N	0	.	.	283	285	GAC	892	894	GAC	174;176;175	G,C;A;C	173,1;176;175	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	2060	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1743	147.3	1	SNP	p	G45D	1	.	.	133	135	GAC	692	694	GAC	248;246;245	G;A,G;C	248;245,1;245	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1120	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1392	100.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5256	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3457	189.5	1	SNP	p	D86N	0	.	.	256	258	GAC	826	828	GAC	250;251;249	G;A,C,G;C	250;249,1,1;249	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5256	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3457	189.5	1	SNP	p	S87R	0	.	.	259	261	AGT	829	831	AGT	248;250;250	A;G;T	248;250;249	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5256	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3457	189.5	1	SNP	p	S87W	0	.	.	259	261	AGT	829	831	AGT	248;250;250	A;G;T	248;250;249	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5256	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3457	189.5	1	SNP	p	S87I	0	.	.	259	261	AGT	829	831	AGT	248;250;250	A;G;T	248;250;249	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5256	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3457	189.5	1	SNP	p	S88P	0	.	.	262	264	TCC	832	834	TCC	249;250;250	T;C;C	248;250;250	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4534	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3202	176.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1825	1827	GGC	245;245;246	G,C;G;C,G	244,1;245;245,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1501	1503	GCA	241;243;245	G,C;C;A	240,1;243;245	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1504	1506	ATC	243;244;242	A;T;C	243;244;242	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1516	1518	GTG	246;249;249	G,T;T,G;G	245,1;248,1;249	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1516	1518	GTG	246;249;249	G,T;T,G;G	245,1;248,1;249	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2020	2022	ACC	249;248;247	A,T;C,T;C,T	248,1;247,1;246,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2074	2076	GCG	273;274;273	G,T;C;G,T	272,1;274;272,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2074	2076	GCG	273;274;273	G,T;C;G,T	272,1;274;272,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2197	2199	GGC	251;250;252	G,T;G;C,A	250,1;250;251,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2206	2208	GGC	246;247;246	G;G;C	246;247;246	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4250	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2876	184.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2224	2226	CCG	244;246;247	C,G;C;G,A	242,2;246;246,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5698	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3576	198.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1862	1864	CTG	226;226;224	C;T;G	226;226;224	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2654	porA	1146	1146	99.83	porA.l6.c30.ctg.1	2350	140.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	866	866	C	200	C	200	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	G38E	NONSYN	112	114	GGA	585	587	GAA	278;280;278	G,C;A;A	277,1;280;278	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	S46G	NONSYN	136	138	AGC	609	611	GGC	278;279;280	G;G;C	278;279;280	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	615	617	GGA	279;279;280	G;G;A,C	279;279;279,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	T87A	NONSYN	259	261	ACT	732	734	GCT	224;224;224	G;C;T	224;224;224	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	738	740	AGC	223;225;225	A;G;C	223;225;225	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	.	MULTIPLE	358	359	AA	830	831	CG	227;224	C;G,A	227;223,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	.	MULTIPLE	361	362	GA	833	835	CAG	222;225;225	C,G;A,G;G,A	221,1;224,1;224,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	N122K	NONSYN	364	366	AAC	837	839	AAA	223;222;226	A,G;A;A	222,1;222;226	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	K143E	NONSYN	427	429	AAA	900	902	GAA	225;226;225	G;A,G;A	224;224,1;224	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	924	926	GCA	235;232;233	G;C;A	235;232;233	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1116	1118	ACT	243;245;247	A;C,A;T	243;244,1;247	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1125	1127	ATG	241;240;238	A;T;G	241;240;238	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1239	1241	GCA	219;220;220	G,A;C,T;A	218,1;219,1;220	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1242	1244	ACG	218;216;218	A;C;G	218;216;218	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	S258R	NONSYN	772	774	AGT	1245	1247	AGG	224;225;224	A;G,T;G	224;224,1;224	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1248	1250	GTT	222;224;226	G;T;T	222;224;226	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1308	1310	GTA	227;226;223	G;T;A	227;226;223	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1347	1349	ACT	223;224;226	A;C;T	223;224;226	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1353	1355	GAT	236;236;237	G;A;T	236;236;237	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1365	1367	CAC	233;234;236	C;A;C	233;234;236	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	1	SNP	p	G120K	1	.	.	358	360	AAG	830	832	CGG	227;224;222	C;G,A;G	227;223,1;222	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	1	SNP	p	D121N	0	.	.	361	363	GAC	833	836	CGC	222;225;227	C,G;G,A;C,A	221,1;224,1;226,1	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2808	porB1b	1047	1047	97.14	porB1b.l15.c30.ctg.1	1689	206.5	1	SNP	p	A121D	1	.	.	361	363	GAC	833	836	CGC	222;225;227	C,G;G,A;C,A	221,1;224,1;226,1	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	S273T	NONSYN	817	819	TCG	53	55	ACT	47;47;47	A;C;T	47;47;47	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	D276S	NONSYN	826	828	GAT	62	64	AGT	47;47;47	A;G;T	47;47;47	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	K278D	NONSYN	832	834	AAA	68	70	GAC	47;47;47	G;A;C	47;47;47	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	R279H	NONSYN	835	837	CGC	71	73	CAC	47;47;47	C;A;C	47;47;47	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	Q308R	NONSYN	922	924	CAA	158	160	CGA	1;1;1	C;G;A	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	E309trunc	TRUNC	925	925	G	161	161	T	1	T	1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	E313A	NONSYN	937	939	GAA	173	175	GCA	1;1;1	G;C;A	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	N314D	NONSYN	940	942	AAC	176	178	GAC	1;1;1	G;A;C	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	F316I	NONSYN	946	948	TTC	182	184	ATC	1;1;1	A;T;C	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	A318S	NONSYN	952	954	GCG	188	190	TCG	1;1;1	T;C;G	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	G321S	NONSYN	961	963	GGC	197	199	AGC	1;1;1	A;G;C	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	G322A	NONSYN	964	966	GGT	200	202	GCC	1;1;1	G;C;C	1;1;1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	204	porB3	990	226	90.71	porB3.l15.c17.ctg.2	241	25.0	0	.	p	.	0	F329C	NONSYN	985	987	TTC	221	223	TGC	2;2;2	T;G,T;C	2;1,1;2	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10316	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5275	243.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2164	2166	AAT	237;236;237	A;A;T	237;236;237	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1572	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1454	134.3	1	SNP	p	V57M	1	.	.	169	171	ATG	762	764	ATG	272;273;270	A;T,A;G,C,A	272;272,1;268,1,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
